ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) (TNBC)
A Phase III, Multicenter, Randomized Study of ABX Plus Cisplatin (AP) Versus Gemcitabine Plus Cisplatin (GP) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer
Sponsor: Fudan University
This PHASE3 trial investigates Breast Cancer and is currently completed. Fudan University leads this study, which shows 9 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Mar 2022 — May 2022 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE3
▶ Show 4 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting · Phase: PHASE2 → PHASE3
-
Mar 2019 — Mar 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fudan University
For direct contact, visit the study record on ClinicalTrials.gov .